Update of fecal markers of inflammation in inflammatory bowel disease

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 10, 2011, Pages 1493-1499

  Judd, Thomas A ^a   Day, Andrew S ^a,b,d   Lemberg, Daniel A ^b   Turner, Dan ^c   Leach, Steven T ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b SYDNEY CHILDREN'S HOSPITAL   (Australia)

^c SHAARE ZEDEK MEDICAL CENTER   (Israel)

^d UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Calprotectin; Fecal marker; Inflammatory bowel disease; Lactoferrin; M2 pyruvate kinase; S100A12

Indexed keywords

ALBUMIN; ALPHA 1 ANTITRYPSIN; BIOCHEMICAL MARKER; C REACTIVE PROTEIN; CALCIUM BINDING PROTEIN; CALGRANULIN; CALGRANULIN A; CALGRANULIN B; CORTICOSTEROID; LACTOFERRIN; LEUKOCYTE ELASTASE; MYELOPEROXIDASE; PYRUVATE KINASE; PYRUVATE KINASE M2; S100A12 PROTEIN; UNCLASSIFIED DRUG;

CORTICOSTEROID THERAPY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENDOSCOPY; ENTERITIS; ERYTHROCYTE SEDIMENTATION RATE; FECES ANALYSIS; FECES LEVEL; HUMAN; INTESTINE MUCOSA; IRRITABLE COLON; LEUKOCYTE MIGRATION; LYMPHOCYTIC INFILTRATION; NEUTROPHIL; POLYMORPHONUCLEAR CELL; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RELAPSE; REVIEW; RISK FACTOR; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY; ULCERATIVE COLITIS;

EID: 80053101697     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06846.x     Document Type: Review

References (72)

1. Canani RB, Terrin G, Rapacciuolo L etal. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig. Liver Dis. 2008; 40: 547-53.
2. Leach ST, Day AS. S100 proteins in the pathogenesis and diagnosis of inflammatory bowel disease. Expert Rev. Clin. Immunol. 2006; 2: 471-80.
3. Ramasundara M, Leach ST, Lemberg DA, Day AS. Defensins and inflammation: the role of defensins in inflammatory bowel disease. J. Gastroenterol. Hepatol. 2009; 24: 202-8.
4. Chong SK, Blackshaw AJ, Boyle S, Williams CB, Walker-Smith JA. Histological diagnosis of chronic inflammatory bowel disease in childhood. Gut 1985; 26: 55-9.
5. Price AB, Morson BC. Inflammatory bowel disease: the surgical pathology of Crohn's disease and ulcerative colitis. Hum. Pathol. 1975; 6: 7-29.
6. Surawicz CM, Meisel JL, Ylvisaker T, Saunders DR, Rubin CE. Rectal biopsy in the diagnosis of Crohn's disease: value of multiple biopsies and serial sectioning. Gastroenterology 1981; 80: 66-71.
7. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006; 55: 426-31.
8. Elliott EJ. Acute gastroenteritis in children. BMJ 2007; 334: 35-40.
9. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am. J. Gastroenterol. 2008; 103: 162-9.
10. Crama-Bohbouth G, Pena AS, Biemond I etal. Are activity indices helpful in assessing active intestinal inflammation in Crohn's disease? Gut 1989; 30: 1236-40.
11. Sutherland AD, Gearry RB, Frizelle FA. Review of fecal biomarkers in inflammatory bowel disease. Dis. Colon Rectum 2008; 51: 1283-91.
12. Desai D, Faubion WA, Sandborn WJ. Review article: biological activity markers in inflammatory bowel disease. Aliment. Pharmacol. Ther. 2007; 25: 247-55.
13. Fischbach W, Becker W, Mossner J, Koch W, Reiners C. Faecal alpha-1-antitrypsin and excretion of 111indium granulocytes in assessment of disease activity in chronic inflammatory bowel diseases. Gut 1987; 28: 386-93.
14. Peterson CGB, Eklund E, Taha Y, Raab Y, Carlson M. A new method for the quantification of neutrophil and eosinophil cationic proteins in feces: establishment of normal levels and clinical application in patients with inflammatory bowel disease. Am. J. Gastroenterol. 2002; 97: 1755-62.
15. Sangfelt P, Carlson M, Thorn M, Loof L, Raab Y. Neutrophil and eosinophil granule proteins as markers of response to local prednisolone treatment in distal ulcerative colitis and proctitis. Am. J. Gastroenterol. 2001; 96: 1085-90.
16. Wagner M, Peterson CGB, Ridefelt P, Sangfelt P, Carlson M. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J. Gastroenterol. 2008; 14: 5584-9.
17. Masoodi I, Kochhar R, Dutta U etal. Fecal lactoferrin, myeloperoxidase and serum C-reactive are effective biomarkers in the assessment of disease activity and severity in patients with idiopathic ulcerative colitis. J. Gastroenterol. Hepatol. 2009; 24: 1768-74.
18. Nauseef WM, Malech HL. Analysis of the peptide subunits of human neutrophil myeloperoxidase. Blood 1986; 67: 1504-7.
19. Costa F, Mumolo MG, Ceccarelli L etal. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005; 54: 364-8.
20. Foell D, Wittkowski H, Vogl T, Roth J. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J. Leukoc. Biol. 2007; 81: 28-37.
21. Leach ST, Yang Z, Messina I etal. Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease. Scand. J. Gastroenterol. 2007; 42: 1321-31.
22. Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig. Liver Dis. 2009; 41: 56-66.
23. Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm. Bowel Dis. 2006; 12: 524-34.
24. Joishy M, Davies I, Ahmed M etal. Fecal calprotectin and lactoferrin as noninvasive markers of pediatric inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 2009; 48: 48-54.
25. Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand. J. Gastroenterol. 1999; 34: 50-4.
26. Campeotto F, Butel MJ, Kalach N etal. High faecal calprotectin concentrations in newborn infants. Arch. Dis. Child. Fetal Neonatal Ed. 2004; 89: F353-5.
27. Olafsdottir E, Aksnes L, Fluge G, Berstad A. Faecal calprotectin levels in infants with infantile colic, healthy infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children. Acta Paediatr. 2002; 91: 45-50.
28. Rugtveit J, Fagerhol MK. Age-dependent variations in fecal calprotectin concentrations in children. J. Pediatr. Gastroenterol. Nutr. 2002; 34: 323-4. author reply 4-5.
29. Husebye E, Ton H, Johne B. Biological variability of fecal calprotectin in patients referred for colonoscopy without colonic inflammation or neoplasm. Am. J. Gastroenterol. 2001; 96: 2683-7.
30. Tibble J, Teahon K, Thjodleifsson B etal. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000; 47: 506-13.
31. Bunn SK, Bisset WM, Main MJ, Golden BE. Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 2001; 32: 171-7.
32. Bunn SK, Bisset WM, Main MJ, Gray ES, Olson S, Golden BE. Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 2001; 33: 14-22.
33. von Roon AC, Karamountzos L, Purkayastha S etal. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am. J. Gastroenterol. 2007; 102: 803-13.
34. van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010; 341: c3369.
35. Costa F, Mumolo MG, Bellini M etal. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig. Liver Dis. 2003; 35: 642-7.
36. Langhorst J, Elsenbruch S, Mueller T etal. Comparison of 4 neutrophil-derived proteins in feces as indicators of disease activity in ulcerative colitis. Inflamm. Bowel Dis. 2005; 11: 1085-91.
37. Sidler MA, Leach ST, Day AS. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children. Inflamm. Bowel Dis. 2008; 14: 359-66.
38. D'Inca R, Dal Pont E, Di Leo V etal. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int. J. Colorectal Dis. 2007; 22: 429-37.
39. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119: 15-22.
40. Fagerberg UL, Loof L, Lindholm J, Hansson L-O, Finkel Y. Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 2007; 45: 414-20.
41. Roseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand. J. Gastroenterol. 2004; 39: 1017-20.
42. Foell D, Kucharzik T, Kraft M etal. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut 2003; 52: 847-53.
43. Yang Z, Tao T, Raftery MJ, Youssef P, Di Girolamo N, Geczy CL. Proinflammatory properties of the human S100 protein S100A12. J. Leukoc. Biol. 2001; 69: 986-94.
44. Hofmann MA, Drury S, Fu C etal. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999; 97: 889-901.
45. de Jong NS, Leach ST, Day AS. Fecal S100A12: a novel noninvasive marker in children with Crohn's disease. Inflamm. Bowel Dis. 2006; 12: 566-72.
46. Foell D, Kane D, Bresnihan B etal. Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatology (Oxford) 2003; 42: 1383-9.
47. Marenholz I, Heizmann CW, Fritz G. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem. Biophys. Res. Commun. 2004; 322: 1111-22.
48. Foell D, Seeliger S, Vogl T etal. Expression of S100A12 (EN-RAGE) in cystic fibrosis. Thorax 2003; 58: 613-17.
49. Kaiser T, Langhorst J, Wittkowski H etal. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut 2007; 56: 1706-13.
50. Fagerberg UL, Loof L, Myrdal U, Hansson LO, Finkel Y. Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J. Pediatr. Gastroenterol. Nutr. 2005; 40: 450-5.
51. Manolakis AC, Kapsoritakis AN, Georgoulias P etal. Moderate performance of serum S100A12, in distinguishing inflammatory bowel disease from irritable bowel syndrome. BMC Gastroenterol. 2010; 10: 118.
52. Baveye S, Elass E, Mazurier J, Spik G, Legrand D. Lactoferrin: a multifunctional glycoprotein involved in the modulation of the inflammatory process. Clin. Chem. Lab. Med. 1999; 37: 281-6.
53. Baynes RD, Bezwoda WR. Lactoferrin and the inflammatory response. Adv. Exp. Med. Biol. 1994; 357: 133-41.
54. Kane SV, Sandborn WJ, Rufo PA etal. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am. J. Gastroenterol. 2003; 98: 1309-14.
55. Levay PF, Viljoen M. Lactoferrin: a general review. Haematologica 1995; 80: 252-67.
56. Angriman I, Scarpa M, D'Inca R etal. Enzymes in feces: useful markers of chronic inflammatory bowel disease. Clin. Chim. Acta 2007; 381: 63-8.
57. Sugi K, Saitoh O, Hirata I, Katsu K. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am. J. Gastroenterol. 1996; 91: 927-34.
58. Dai J, Liu W-Z, Zhao Y-P, Hu Y-B, Ge Z-Z. Relationship between fecal lactoferrin and inflammatory bowel disease. Scand. J. Gastroenterol. 2007; 42: 1440-4.
59. Kayazawa M, Saitoh O, Kojima K etal. Lactoferrin in whole gut lavage fluid as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am. J. Gastroenterol. 2002; 97: 360-9.
60. Sipponen T, Savilahti E, Kolho K-L, Nuutinen H, Turunen U, Farkkila M. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm. Bowel Dis. 2008; 14: 40-6.
61. Walker TR, Land ML, Kartashov A etal. Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 2007; 44: 414-22.
62. Silberer H, Kuppers B, Mickisch O etal. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome. Clin. Lab. 2005; 51: 117-26.
63. Fine KD, Ogunji F, George J, Niehaus MD, Guerrant RL. Utility of a rapid fecal latex agglutination test detecting the neutrophil protein, lactoferrin, for diagnosing inflammatory causes of chronic diarrhea. Am. J. Gastroenterol. 1998; 93: 1300-5.
64. Chung-Faye G, Hayee B, Maestranzi S, Donaldson N, Forgacs I, Sherwood R. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation. Inflamm. Bowel Dis. 2007; 13: 1374-8.
65. Czub E, Herzig K-H, Szaflarska-Popawska A etal. Fecal pyruvate kinase: a potential new marker for intestinal inflammation in children with inflammatory bowel disease. Scand. J. Gastroenterol. 2007; 42: 1147-50.
66. Walkowiak J, Banasiewicz T, Krokowicz P, Hansdorfer-Korzon R, Drews M, Herzig K-H. Fecal pyruvate kinase (M2-PK): a new predictor for inflammation and severity of pouchitis. Scand. J. Gastroenterol. 2005; 40: 1493-4.
67. McDowell G, Gupta S, Dellerba M, Coppinger T, Levy RD, Keevil BG. Plasma concentrations of tumour dimeric pyruvate kinase are increased in patients with chronic cardiac failure. Ann. Clin. Biochem. 2004; 41: 491-3.
68. Oehler R, Weingartmann G, Manhart N etal. Polytrauma induces increased expression of pyruvate kinase in neutrophils. Blood 2000; 95: 1086-92.
69. Hardt PD, Mazurek S, Toepler M etal. Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer. Br. J. Cancer 2004; 91: 980-4.
70. Sipos F, Molnar B, Zagoni T, Berczi L, Tulassay Z. Growth in epithelial cell proliferation and apoptosis correlates specifically to the inflammation activity of inflammatory bowel diseases: ulcerative colitis shows specific p53- and EGFR expression alterations. Dis. Colon Rectum 2005; 48: 775-86.
71. Turner D, Leach ST, Mack D etal. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Gut 2010; 59: 1207-12.
72. Turner D, Mack D, Leleiko N etal. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology 2010; 138: 2282-91.